Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2025
Reporting Period: Events occurring between January 27, 2025, and February 18, 2025.
Business Context: The Company is a Cayman Islands-based Special Purpose Acquisition Company (SPAC) that recently consummated its Initial Public Offering (IPO) and subsequently exercised an over-allotment option.
Key Financial Metrics
- Total Gross Proceeds (IPO + Over-Allotment): $230,000,000 ($200,000,000 from initial IPO + $30,000,000 from over-allotment).
- Private Placement Proceeds: $4,300,000 total ($4,000,000 initial + $300,000 additional).
- Trust Account Balance: $231,150,000 placed in trust for public shareholders.
- Subscription Receivable: $1,100,000 (portion of initial private placement not yet received).
- Units Issued: 23,000,000 total public units (20,000,000 initial + 3,000,000 over-allotment).
- Offering Price: $10.00 per Unit.
Material Changes vs. Prior Period
This filing reports the completion of the over-allotment option exercise, which was not present in the initial IPO filing dated January 27, 2025. Key changes include:
- Capital Raised: An additional $30,000,000 in gross proceeds from the sale of 3,000,000 Over-Allotment Option Units.
- Private Placement Expansion: An additional 30,000 Private Units sold to the Sponsor for $300,000.
- Trust Account Increase: The total amount deposited into the trust account increased to $231,150,000 to reflect the new capital.
Guidance, Outlook, and Risks
Management Commentary: The Company confirmed the full exercise of the underwriters' 45-day over-allotment option on February 13, 2025, with closing on February 18, 2025. The additional private units were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 as non-public offerings.
Risks and Contingencies:
- Receivables: As of the filing date, $1,100,000 of the initial private placement proceeds remains outstanding as a subscription receivable.
- Pro-Forma Financials: The filing includes a pro-forma balance sheet (Exhibit 99.1) reflecting the over-allotment exercise, indicating that final financial statements are subject to the completion of these transactions.
Investor Verification Checklist
- Verify the final cash balance in the trust account against the reported $231,150,000.
- Confirm the status of the $1,100,000 subscription receivable from the Sponsor.
- Review Exhibit 99.1 (Pro-Forma Balance Sheet) for updated equity and liability positions.
- Monitor the Company's progress toward identifying a target business combination within the required timeframe.